Yujiro Hata, Ideaya Biosciences CEO

Ideaya goes for­ward with $150M of­fer­ing af­ter tout­ing PhII can­cer da­ta

Ideaya Bio­sciences has lift­ed the cov­er on some da­ta for its metasta­t­ic uveal melanoma (MUM) treat­ment while al­so forg­ing ahead with an of­fer­ing of its stock.

Over the week­end, Ideaya dropped in­ter­im re­sults from its Phase II clin­i­cal tri­al in­ves­ti­gat­ing a com­bi­na­tion of darovasert­ib and crizo­tinib to treat MUM. On top of these da­ta, the biotech is mov­ing ahead with an of­fer­ing of up to $150 mil­lion of shares of its com­mon stock in a pub­lic of­fer­ing.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.